BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 24129299)

  • 1. [Extracranial stereotactic radiotherapy for early-stage non-small cell lung cancer and oligometastases].
    Riesterer O
    Praxis (Bern 1994); 2013 Oct; 102(21):1309-16. PubMed ID: 24129299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of extracranial stereotactic body radiation therapy (SBRT) added to standard treatment in patients with solid tumors (breast, prostate and non-small cell lung cancer) with up to 3 bone-only metastases: study protocol for a randomised phase III trial (STEREO-OS).
    Thureau S; Marchesi V; Vieillard MH; Perrier L; Lisbona A; Leheurteur M; Tredaniel J; Culine S; Dubray B; Bonnet N; Asselain B; Salleron J; Faivre JC
    BMC Cancer; 2021 Feb; 21(1):117. PubMed ID: 33541288
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Stereotactic body radiotherapy for malignant nodules in the lung].
    Nestle U; Guckenberger M
    Zentralbl Chir; 2013 Oct; 138 Suppl 1():S25-31. PubMed ID: 24150852
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [An analysis of 20 consecutive patients treated with stereotactic body radiotherapy on Novalis Tx(®) for stage I non-small-cell lung cancer].
    Guillerme F; Clavier JB; Schumacher C; Falcoz PE; Bourrhala K; Santelmo N; Hassler S; Schott R; Quoix E; Massard G; Noël G
    Cancer Radiother; 2013; 17(4):272-81. PubMed ID: 23712043
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stereotactic Ablative Body Radiotherapy (SABR) in Pulmonary Oligometastatic/Oligorecurrent Non-small Cell Lung Cancer Patients: A New Therapeutic Approach.
    Agolli L; Valeriani M; Nicosia L; Bracci S; De Sanctis V; Minniti G; Enrici RM; Osti MF
    Anticancer Res; 2015 Nov; 35(11):6239-45. PubMed ID: 26504057
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Once-weekly, high-dose stereotactic body radiotherapy for lung cancer: 6-year analysis of 60 early-stage, 42 locally advanced, and 7 metastatic lung cancers.
    Salazar OM; Sandhu TS; Lattin PB; Chang JH; Lee CK; Groshko GA; Lattin CJ
    Int J Radiat Oncol Biol Phys; 2008 Nov; 72(3):707-15. PubMed ID: 18455322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stereotactic body radiation therapy (stereotactic ablative radiotherapy) for stage I non-small cell lung cancer--updates of radiobiology, techniques, and clinical outcomes.
    Hadziahmetovic M; Loo BW; Timmerman RD; Mayr NA; Wang JZ; Huang Z; Grecula JC; Lo SS
    Discov Med; 2010 May; 9(48):411-7. PubMed ID: 20515609
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of tumor size on outcomes after stereotactic body radiation therapy for medically inoperable early-stage non-small cell lung cancer.
    Allibhai Z; Taremi M; Bezjak A; Brade A; Hope AJ; Sun A; Cho BC
    Int J Radiat Oncol Biol Phys; 2013 Dec; 87(5):1064-70. PubMed ID: 24210082
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stereotactic body radiotherapy for centrally located early-stage non-small cell lung cancer or lung metastases from the RSSearch(®) patient registry.
    Davis JN; Medbery C; Sharma S; Pablo J; Kimsey F; Perry D; Muacevic A; Mahadevan A
    Radiat Oncol; 2015 May; 10():113. PubMed ID: 25975848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of outcomes following stereotactic body radiotherapy for non-small cell lung cancer in patients with and without pathological confirmation.
    Haidar YM; Rahn DA; Nath S; Song W; Bazhenova L; Makani S; Fuster MM; Sandhu AP
    Ther Adv Respir Dis; 2014 Feb; 8(1):3-12. PubMed ID: 24334338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Stereotactic Body Radiotherapy for Early Stage NSCLC - What Is the Evidence?].
    Guckenberger M
    Zentralbl Chir; 2017 Sep; 142(S 01):S17-S25. PubMed ID: 28958106
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 30 Gy or 34 Gy? Comparing 2 single-fraction SBRT dose schedules for stage I medically inoperable non-small cell lung cancer.
    Videtic GM; Stephans KL; Woody NM; Reddy CA; Zhuang T; Magnelli A; Djemil T
    Int J Radiat Oncol Biol Phys; 2014 Sep; 90(1):203-8. PubMed ID: 25015198
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stereotactic ablative radiotherapy (SABR) for non-small cell lung cancer.
    Iyengar P; Westover K; Timmerman RD
    Semin Respir Crit Care Med; 2013 Dec; 34(6):845-54. PubMed ID: 24258574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors important for efficacy of stereotactic body radiotherapy of medically inoperable stage I lung cancer. A retrospective analysis of patients treated in the Nordic countries.
    Baumann P; Nyman J; Lax I; Friesland S; Hoyer M; Rehn Ericsson S; Johansson KA; Ekberg L; Morhed E; Paludan M; Wittgren L; Blomgren H; Lewensohn R
    Acta Oncol; 2006; 45(7):787-95. PubMed ID: 16982541
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CyberKnife radiosurgery for stage I lung cancer: results at 36 months.
    Brown WT; Wu X; Fayad F; Fowler JF; Amendola BE; García S; Han H; de la Zerda A; Bossart E; Huang Z; Schwade JG
    Clin Lung Cancer; 2007 Sep; 8(8):488-92. PubMed ID: 17922973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of stereotactic body radiotherapy for stage 1 non-small-cell lung cancer in routine clinical practice: a patterns-of-care and outcome analysis.
    Guckenberger M; Allgäuer M; Appold S; Dieckmann K; Ernst I; Ganswindt U; Holy R; Nestle U; Nevinny-Stickel M; Semrau S; Sterzing F; Wittig A; Andratschke N
    J Thorac Oncol; 2013 Aug; 8(8):1050-8. PubMed ID: 23817193
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stereotactic radiotherapy reduces treatment cost while improving overall survival and local control over standard fractionated radiation therapy for medically inoperable non-small-cell lung cancer.
    Lanni TB; Grills IS; Kestin LL; Robertson JM
    Am J Clin Oncol; 2011 Oct; 34(5):494-8. PubMed ID: 20805737
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medically inoperable peripheral lung cancer treated with stereotactic body radiation therapy.
    Kelley KD; Benninghoff DL; Stein JS; Li JZ; Byrnes RT; Potters L; Knisely JP; Zinkin HD
    Radiat Oncol; 2015 May; 10():120. PubMed ID: 26018408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive factors for local control in primary and metastatic lung tumours after four to five fraction stereotactic ablative body radiotherapy: a single institution's comprehensive experience.
    Thibault I; Poon I; Yeung L; Erler D; Kim A; Keller B; Lochray F; Jain S; Soliman H; Cheung P
    Clin Oncol (R Coll Radiol); 2014 Nov; 26(11):713-9. PubMed ID: 25085765
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stereotactic radiotherapy of histologically proven inoperable stage I non-small cell lung cancer: patterns of failure.
    Andratschke N; Zimmermann F; Boehm E; Schill S; Schoenknecht C; Thamm R; Molls M; Nieder C; Geinitz H
    Radiother Oncol; 2011 Nov; 101(2):245-9. PubMed ID: 21724287
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.